TEL inhibitors are a class of chemical compounds specifically designed to target and inhibit the function of TEL, also known as ETV6 (ETS Variant 6), a member of the ETS family of transcription factors. TEL is a nuclear protein that plays a critical role in regulating gene expression, particularly in hematopoiesis (the formation of blood cells) and the development of various tissues. It functions primarily as a transcriptional repressor, binding to specific DNA sequences and recruiting corepressors to inhibit the transcription of target genes. TEL is involved in controlling processes such as cell proliferation, differentiation, and apoptosis by regulating the expression of genes that are critical for these pathways. By inhibiting TEL, researchers can disrupt these regulatory processes, providing a powerful tool to study the specific roles of TEL in gene expression, cell fate determination, and the maintenance of cellular homeostasis.
In research settings, TEL inhibitors are valuable tools for exploring the molecular mechanisms by which TEL influences transcriptional regulation and the broader implications of this regulation on cellular function and development. By blocking TEL activity, scientists can investigate how the inhibition affects the expression of TEL target genes, particularly focusing on the role of TEL in the regulation of hematopoietic stem cells and the differentiation of various blood cell lineages. This inhibition allows researchers to study the downstream effects on cellular processes such as proliferation, survival, and differentiation, offering insights into how TEL contributes to the maintenance of normal cellular function and how its dysregulation might lead to developmental abnormalities or disease states. Additionally, TEL inhibitors provide insights into the interactions between TEL and other transcription factors, as well as the coregulatory complexes that modulate its activity, shedding light on the complex networks that govern transcriptional control and cellular identity. Through these studies, the use of TEL inhibitors enhances our understanding of the critical role of transcription factors in gene regulation, the mechanisms of cellular differentiation, and the broader implications of transcriptional repression in maintaining tissue homeostasis and function.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Inhibits BCR-ABL and SRC family kinases, impacting signaling in leukemias with ETV6 involvement. | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $209.00 $413.00 | 9 | |
A BCR-ABL inhibitor, used in cases where ETV6 is part of a fusion protein in leukemia. | ||||||
AP 24534 | 943319-70-8 | sc-362710 sc-362710A | 10 mg 50 mg | $175.00 $983.00 | 2 | |
Targets BCR-ABL, including resistant mutations, relevant in ETV6-related leukemia cases. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Inhibits multiple tyrosine kinases, may affect signaling in cancers involving ETV6. | ||||||
Sunitinib Malate | 341031-54-7 | sc-220177 sc-220177A sc-220177B | 10 mg 100 mg 3 g | $197.00 $520.00 $1093.00 | 4 | |
Targets various receptor tyrosine kinases, potentially affecting ETV6-related pathways. | ||||||
Pazopanib | 444731-52-6 | sc-396318 sc-396318A | 25 mg 50 mg | $130.00 $182.00 | 2 | |
Inhibits VEGF receptors and other kinases, could impact signaling in ETV6-related cancers. | ||||||
Lestaurtinib | 111358-88-4 | sc-218657 sc-218657A sc-218657B | 1 mg 5 mg 10 mg | $275.00 $326.00 $612.00 | 3 | |
Targets JAK2 and FLT3, kinases involved in pathways potentially linked with ETV6. | ||||||
PKC-412 | 120685-11-2 | sc-200691 sc-200691A | 1 mg 5 mg | $52.00 $114.00 | 10 | |
Inhibits FLT3 and other kinases, possibly affecting leukemias with ETV6 involvement. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
A JAK1/2 inhibitor, might affect signaling pathways in cancers involving ETV6. | ||||||